{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:47:04Z","timestamp":1793674024072,"version":"4.5.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01CA283935"],"award-info":[{"award-number":["U01CA283935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lanepe.2026.101852","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:47:42Z","timestamp":1788479262000},"page":"101852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-4564","authenticated-orcid":false,"given":"Maria","family":"Qurashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace","family":"Lai-Hung Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-0843","authenticated-orcid":false,"given":"Tawesak","family":"Tanwandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf Omar","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-6219","authenticated-orcid":false,"given":"Mohamed","family":"AbdAllah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Hebditch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-3971","authenticated-orcid":false,"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lanepe.2026.101852_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101852_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101852_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101852_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib6","first-page":"38","article-title":"Surveillance and diagnosis of hepatocellular carcinoma","volume":"11","author":"Fitzmorris","year":"2015","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101852_bib7","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101852_bib10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2023.12.031","article-title":"Inequities in primary liver cancer in Europe: the state of play","volume":"80","author":"Kondili","year":"2024","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101852_bib12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s004320050215","article-title":"Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis","volume":"124","author":"del Olmo","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101852_bib13","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cgh.2006.05.013","article-title":"Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis","volume":"4","author":"N'Kontchou","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101852_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101852_bib15","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/hep.24581","article-title":"Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?","volume":"54","author":"Poustchi","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2026.101852_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1722277","article-title":"Three-year of hepatocellular carcinoma surveillance in patients with cirrhosis diagnosed between 2009 and 2013: a cohort study based on the French National Health Data System (SNDS) claims data","volume":"15","author":"Caillet","year":"2025","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101852_bib18","article-title":"Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs","volume":"5","author":"Reggidori","year":"2023","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101852_bib19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jhep.2015.06.012","article-title":"Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands","volume":"63","author":"van Meer","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101852_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.canep.2014.10.005","article-title":"Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway\u2014A population-based cohort study","volume":"38","author":"Eskesen","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101852_bib21","article-title":"Socioeconomic inequalities in diagnostics, care and survival outcomes for hepatocellular carcinoma in Sweden: a nationwide cohort study","volume":"52","author":"Vaz","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101852_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.04.027","article-title":"Compliance with Hepatocellular Carcinoma Surveillance Guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort Study","volume":"155","author":"Costentin","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lanepe.2026.101852_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.03.017","article-title":"Surveillance of patients at risk of liver cancer: expert opinions","author":"Yip","year":"2026","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101852_bib24","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2020.05.043","article-title":"Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis","volume":"73","author":"Jepsen","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/apt.13841","article-title":"Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"45","author":"Simmons","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/hep.28895","article-title":"An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"65","author":"Atiq","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/HEP.0000000000000528","article-title":"Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis","volume":"79","author":"Narasimman","year":"2024","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101852_bib28","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.14309\/ajg.0000000000002015","article-title":"Emerging tools for hepatocellular carcinoma surveillance","volume":"117","author":"Singal","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2023.07.018","article-title":"Financial burden of hepatocellular carcinoma screening in patients with cirrhosis","volume":"22","author":"Narasimman","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2026.101852_bib30","article-title":"Net benefit of surveillance varies by hepatocellular carcinoma risk in patients with cirrhosis","volume":"8","author":"Patel","year":"2026","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101852_bib31","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/1940-6207.CAPR-12-0046","article-title":"Failure rates in the hepatocellular carcinoma surveillance process","volume":"5","author":"Singal","year":"2012","journal-title":"Cancer Prev Res"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.70403","article-title":"Meta-analysis: utilisation of hepatocellular carcinoma surveillance","volume":"63","author":"Tang","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101852_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.28770","article-title":"Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis","volume":"65","author":"Farvardin","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101852_bib34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cgh.2020.06.049","article-title":"Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis","volume":"19","author":"Singal","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2026.101852_bib35","series-title":"EASL liver cancer summit","article-title":"Clinician-reported bias and stigma as barriers to HCC surveillance provision in the United Kingdom","author":"Qurashi","year":"2026"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101852_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.11076","article-title":"Clinician-level knowledge and barriers to hepatocellular carcinoma surveillance","volume":"7","author":"Wong","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lanepe.2026.101852_bib37","article-title":"Improving hepatocellular carcinoma surveillance in the United Kingdom: challenges and solutions","volume":"43","author":"Qurashi","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101852_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)01849-X","article-title":"SAT-427-YI hepatocellular carcinoma surveillance in the United Kingdom: a multi-centre study assessing uptake and inequalities","volume":"80","author":"Qurashi","year":"2024","journal-title":"J Hepatol"},{"issue":"30","key":"10.1016\/j.lanepe.2026.101852_bib39","doi-asserted-by":"crossref","first-page":"958","DOI":"10.15585\/mmwr.mm7130a2","article-title":"Progress toward the elimination of mother-to-child transmission of hepatitis B virus - worldwide, 2016-2021","volume":"71","author":"Khetsuriani","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanepe.2026.101852_bib40","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2147\/JHC.S462303","article-title":"Optimising surveillance in hepatocellular carcinoma: patient-defined obstacles and solutions","volume":"11","author":"Qurashi","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.lanepe.2026.101852_bib41","series-title":"Europe\u2019s beating cancer plan","year":"2021"},{"key":"10.1016\/j.lanepe.2026.101852_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2026.101924","article-title":"Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort","author":"van Son","year":"2026","journal-title":"JHEP Rep"},{"issue":"10125","key":"10.1016\/j.lanepe.2026.101852_bib43","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101852_bib44","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41416-024-02645-3","article-title":"Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality","volume":"130","author":"Burton","year":"2024","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-000998","article-title":"Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis","volume":"10","author":"Cullen","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.lanepe.2026.101852_bib46","author":"Darzi"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101852_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101852_bib48","doi-asserted-by":"crossref","first-page":"463.e1","DOI":"10.1016\/j.medcli.2020.09.022","article-title":"Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH","volume":"156","author":"Reig","year":"2021","journal-title":"Med Clin"},{"issue":"10504","key":"10.1016\/j.lanepe.2026.101852_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101852_bib50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000530079","article-title":"Surveillance, diagnosis, and treatment outcome of hepatocellular carcinoma in Japan: 2023 update","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.lanepe.2026.101852_bib51","first-page":"S1809","article-title":"Changing epidemiology of HCC in Melbourne, Australia: primary outcomes of the prospective homer-2 cohort","volume":"78","author":"Flores","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101852_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.22367","article-title":"Association of nationwide hepatitis B vaccination and antiviral therapy programs with end-stage liver disease burden in Taiwan","volume":"5","author":"Chiang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lanepe.2026.101852_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/epirev\/mxj010","article-title":"Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched","volume":"28","author":"Chien","year":"2006","journal-title":"Epidemiol Rev"},{"issue":"26","key":"10.1016\/j.lanepe.2026.101852_bib54","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101852_bib55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jgh3.12753","article-title":"Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high-risk chronic hepatitis B patients for HCC surveillance in Thailand","volume":"6","author":"Rattananukrom","year":"2022","journal-title":"JGH Open"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0337913","article-title":"Economic evaluation of biomarker-based surveillance for Hepatocellular Carcinoma in Thai patients with Compensated Liver Cirrhosis","volume":"21","author":"Pinjaroen","year":"2026","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70595","article-title":"Hepatocellular carcinoma in Egypt in the post HCV elimination era: changing aetiology, surveillance, and management pathways","volume":"46","author":"El-Kassas","year":"2026","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101852_bib58","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ajg.2012.445","article-title":"Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community","volume":"108","author":"Wang","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101852_bib59","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2767-9764.CRC-23-0075","article-title":"Prediagnostic CT or MRI utilization and outcomes in hepatocellular carcinoma: Seer-medicare database analysis","volume":"3","author":"Karim","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101852_bib60","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101852_bib61","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep4.1735","article-title":"Hepatocellular carcinoma screening process failures in patients with cirrhosis","volume":"5","author":"Marquardt","year":"2021","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hep.23615","article-title":"Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States","volume":"52","author":"Davila","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101852_bib63","series-title":"Primary liver cancer patient survey","author":"Trust","year":"2024"},{"key":"10.1016\/j.lanepe.2026.101852_bib64","series-title":"Primary liver cancer survey: qualitative responses","author":"Trust","year":"2024"},{"key":"10.1016\/j.lanepe.2026.101852_bib65","series-title":"Patient reported stigma in liver disease: a UK survey","author":"Bajaj","year":"2023"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101852_bib66","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/HEP.0000000000001203","article-title":"Value of HCC surveillance in a landscape of emerging surveillance options: perspectives of a multi-stakeholder modified Delphi panel","volume":"82","author":"Singal","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101852_bib67","series-title":"EASL policy statement on liver cancer screening","year":"2022"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101852_bib68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2024.09.008","article-title":"A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis","volume":"168","author":"Marsh","year":"2025","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cgh.2021.08.010","article-title":"Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma","volume":"20","author":"Chalasani","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101852_bib70","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/hep4.1918","article-title":"A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma","volume":"6","author":"Lin","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.lanepe.2026.101852_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.04.012","article-title":"A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma","author":"Taggart","year":"2026","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cgh.2021.02.024","article-title":"Patient preferences for hepatocellular carcinoma surveillance parameters","volume":"20","author":"Woolen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101852_bib73","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/HEP.0000000000000339","article-title":"Screening of liver cancer with abbreviated MRI","volume":"78","author":"Ronot","year":"2023","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.lanepe.2026.101852_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152709","article-title":"Prospective Study of non-contrast, abbreviated MRI for hepatocellular carcinoma surveillance in patients with suboptimal hepatic visualisation on ultrasound","volume":"16","author":"Vithayathil","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101852_bib75","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib76","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/hep.27654","article-title":"High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers","volume":"61","author":"Suh","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101852_bib77","article-title":"Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis","author":"Sharma","year":"2017","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101852_bib78","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.hpb.2016.05.005","article-title":"Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study","volume":"18","author":"Adler","year":"2016","journal-title":"HPB (Oxford)"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101852_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195173","article-title":"Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response","volume":"13","author":"Hamada","year":"2018","journal-title":"PLoS One"},{"issue":"Suppl 3","key":"10.1016\/j.lanepe.2026.101852_bib80","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1093\/infdis\/jiad022","article-title":"Barriers and strategies for hepatitis B and C elimination in Pakistan","volume":"228","author":"Qureshi","year":"2023","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101852_bib81","article-title":"Price of a hepatitis C cure: cost of production and current prices for direct-acting antivirals in 50 countries","volume":"6","author":"Barber","year":"2020","journal-title":"J Virus Erad"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101852_bib82","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S2468-1253(23)00364-3","article-title":"WHO awards Egypt with gold tier status on the path to eliminate hepatitis C","volume":"8","author":"Hassany","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101852_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(26)00093-8","article-title":"Understanding sugar-sweetened beverage tax implementation globally: a 34-year, population-based observational study in 183 countries","volume":"14","author":"Loaeza","year":"2026","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101852_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004792","article-title":"Public health impacts of increasing the minimum unit price for alcohol in Scotland: a model-based appraisal","volume":"23","author":"Holmes","year":"2026","journal-title":"PLoS Med"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:17:39Z","timestamp":1793632659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":84,"alternative-id":["S2666776226002644"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101852","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101839","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101837","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101861","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101852"}}